Global Alzheimer's Disease Therapeutics and Diagnostics Market 2018-2028 - Visiongain Report

LONDON, July 2, 2018 /PRNewswire/ --

Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies

The Alzheimer's Disease Therapeutics and Diagnostics Market will reach $7.93bn in 2018. The Alzheimer's Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 12.1% in the second half of the forecast period.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 208-page report you will receive 62 tables and 82 figures- all unavailable elsewhere.

The 208-page report provides clear detailed insight into the Alzheimer's Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Alzheimer's Disease Market forecasts from 2018-2028, further broken down into:
• Alzheimer's Drugs Market
• Alzheimer's Diagnostics Market

• Quantitative analysis of the Alzheimer's drug market from 2018 to 2028. It includes analysis and forecast of top drugs and pipeline drugs in the market:
• Namenda
• Aricept
• Exelon
• Solanezumab
• Gantenerumab
• Verubecestat

• Quantitative analysis of the Alzheimer's diagnostics market from 2018-2028. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer's diagnosis from 2018 to 2028:
• Diagnostic biomarker market
• Others

• Profiles of leading pharma companies involved in developing Alzheimer's drugs globally. It contains overviews of the companies' segments, recent mergers and acquisitions and analysis of the companies' recent financial performances. It also includes the details of the drugs for Alzheimer's in the pipeline and forecast of the company drugs available in the market:
• Pfizer
• Eisai
• Actavis
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx
• vTv Therapeutics

• Profiles of leading companies developing diagnostics tests for Alzheimer's disease:
• Eli Lilly
• Amarantus Biosciences Holdings
• Piramal Enterprises
• GE Healthcare
• Navidea
• DiaGenic

• This report also breaks down the revenue forecast for the Alzheimer's Disease Market by national market:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• Brazil
• India
• Russia

• This report covers the qualitative analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.

• This report shows transcripts of research interviews conducted by visiongain:
• David Hung, Chief Executive Officer of Axovant Sciences Inc.
• Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
• Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.

Buy our report today Global Alzheimer's Disease Therapeutics and Diagnostics Market 2018-2028: Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/report/global-alzheimers-disease-therapeutics-and-diagnostics-market-2018-2028

AbbVie
AB Science 
AC Immune
Acadia Pharmaceuticals
Accera
Actavis
Adamas Pharmceuticals 
Affiris 
Allergan
Amarantus BioSciences
Amorphis
Amgen
Archer Pharmaceuticals
Astellas Pharma
Astex
AstraZeneca
Avanir Pharmaceuticals 
Avineuro Pharmaceuticals
Axovant Sciences Inc
AZ Therapies Inc
Baxter
Bayer
Bayer Schering Pharma 
Biogen 
bioMerieux 
Boehringer Ingelheim
Bristol Myers Suibb
Ceregene
Chiesi Farmaceutici
Cognoptix 
Cytos 
Daiichi Sankyo
DiaGenic 
Eisai
Elan
Eli Lilly
EnVivo Pharmaceuticals
European Medicines Agency (EMA)
Forest Laboratories
Forum Pharmaceuticals
Foundation Medical Partners
Functional Neuromodulation 
Food and Drug Administration (FDA)
GE Healthcare 
General Electric 
Genervon Biopharmaceuticals
Genesys Capital
GSK 
Hisamitsu Pharmaceutical
Humanetics
IBA Molecular 
J&J
Janssen Alzheimer Immunotherapy Research & Development
Janssen Pharmaceutical K. K 
Kareus Therapeutics 
LabCorp
Luminex 
Lundbeck
Medtronic
Merck & Co
Merz
Meso Scale Diagnostics 
Metabolic Solutions Development Company
MorphoSys
Nanotherapeutics
National Institute of Health (NIH)
National Institute for Health and Care Excellence (NICE) 
Navidea
NextGen Sciences 
Novartis
Novo Nordisk 
Ono Pharmaceutical 
OPKO
Ortho Clinical Diagnostics 
Otsuka Pharmaceutical 
Oxford BioDynamics 
Par Pharmaceuticals 
Pfizer
Piramal Enterprises 
Piramal Imaging 
Proteome Sciences 
ProteoTech
Proterra
QR Pharma
Quanterix 
Raptor Pharmaceutical 
Resverlogix 
Roche
Roche Diagnostics 
Saladax 
Sandoz
Sangamo BioSciences
Sanofi
sGC Pharma
Shionogi
Shire
Siemens Medical Solutions USA 
Somalogic 
Sonexa Therapeutics
Sun Pharma
T3D Therapeutics
Takeda
Targacept
TauRx 
Toyama Chemical
Transition Therapeutics
TransTech Pharma
United Biomedical
VIVUS
Wyeth

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain